| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144294 Antiproliferative or anticarcinogenic agents comprising reaction products of ninhydrin or benzo(f)ninhydrin with 1,5-diaminotetrazole; enzyme inhibitors |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144292 Protease inhibitors such as N-((4'-Methoxy-(1,1'-biphenyl)-4-yl)-sulfonyl-N-methyl-amino)-(4 -hydroxycyclohexan-1-yl)-acetic acid for prophylaxis of neurodegenerative diseases, vision defects, skin disorders or as antiinflammatory agents |
| 07/31/2003 | US20030144291 Substituted indan derivatives |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144284 Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents |
| 07/31/2003 | US20030144283 Amide substituted imidazoquinolines |
| 07/31/2003 | US20030144281 Substituted benzimidazole compounds |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same |
| 07/31/2003 | US20030144275 Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144266 Pyrazolo-triazolo- pyrimidine, triazolo-triazolo-pyrimidine and imidazolo-triazolo-pyrimidine derivatives useful for the treatment of hypertension, inflammation, mast cell degranulation, cardiac hypoxia, and ischemia |
| 07/31/2003 | US20030144259 Exemestane for use in the first-line treatment of metastatic, advanced hormone-dependent breast cancer, particularly in post-menopausal woman; endorcine therapy |
| 07/31/2003 | US20030144252 Bicalutamide and N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4 -amine used as inhibitor of prostate cancer |
| 07/31/2003 | US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance |
| 07/31/2003 | US20030144239 Expression system |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144232 Expression system |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144188 Androgen regulated nucleic acid molecules and encoded proteins |
| 07/31/2003 | US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143735 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 07/31/2003 | US20030143692 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 07/31/2003 | US20030143683 Introducing a nucleotide sequence encoding prefered amino acid sequences in into a host cell and culturing the host cell in which the peptides are expressed from the nucleotide sequence; human therapeutics and diagnostic protein |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143672 Providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes, useful in eliciting immune responses with respect to corresponding wildtype epitopes |
| 07/31/2003 | US20030143667 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143622 Human RNA binding proteins |
| 07/31/2003 | US20030143621 Contacting a cellular component with a reagent which binds to PC-1 (prostate cancer-1) protein |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143559 A modified estrogen receptor alpha ligand binding domain containing an amino acid modification in region 1, at region 2, or atleast one amino acid modifiation in both of regions, and these domain interacts with a nonendogenous ligand |
| 07/31/2003 | US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143232 Incubating survivin and p34cdc2-cyclin B1 kinase complex in presence of an agent; determining whether agent modulates phosphorylation of survivin by p34cdc2-cyclin B1 kinase complex, identifying an agent which modulates phosphorylation |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143209 For gene therapy of cancers or cardiovascular conditions |
| 07/31/2003 | US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal |
| 07/31/2003 | US20030143190 For modulating the immune system; therapy of cancer |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143165 Regularly applying a topical formulation to the skin of patient, formulation containing a pharmaceutically effective amount of a non- steroidal anti-inflammatory drug |
| 07/31/2003 | US20030143161 Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment |
| 07/31/2003 | US20030143157 Method of treating tumors |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2474322A1 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2473924A1 Systems and methods for photodynamic therapy |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473763A1 Compounds for modulating cell proliferation |
| 07/31/2003 | CA2473748A1 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | CA2473740A1 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2472775A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
| 07/31/2003 | CA2472729A1 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 07/31/2003 | CA2472578A1 Anti-cancer combination and use thereof |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2472186A1 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | CA2471749A1 Biocidal compounds and their preparation |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | CA2469685A1 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/30/2003 | EP1331269A1 Novel protein, process for producing the same and use thereof |
| 07/30/2003 | EP1331224A1 Thiazole or oxazole derivatives |
| 07/30/2003 | EP1331005A1 Medicinal compositions for concominant use as anticancer atent |
| 07/30/2003 | EP1330543A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 07/30/2003 | EP1330538A2 Cd36 as a heat shock protein receptor and uses thereof |
| 07/30/2003 | EP1330535A2 Kini-3 motor protein and methods for its use |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330514A1 Ex vivo oxidatively stressed cll cells in chronic lymphocytic leukemia (cll) treatment |
| 07/30/2003 | EP1330470A1 Glutathione conjugates with distamycin derivatives having antitumor activity |
| 07/30/2003 | EP1330456A2 N8,n13 -disubstituted quino 4,3,2-kl]acridinium salts as therapeutic agents |
| 07/30/2003 | EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 07/30/2003 | EP1330447A2 Peptides as met-ap2 inhibitors |
| 07/30/2003 | EP1330444A2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 07/30/2003 | EP1330442A1 Phthalazinone derivatives |
| 07/30/2003 | EP1330441A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/30/2003 | EP1330439A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 07/30/2003 | EP1330432A2 Substituted alkanoic acids |
| 07/30/2003 | EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 07/30/2003 | EP1330273A1 Coated implantable medical device |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330259A2 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy |
| 07/30/2003 | EP1330258A2 Kahalalide f formulation |
| 07/30/2003 | EP1330254A2 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 07/30/2003 | EP1330251A1 Combination therapy for the treatment of estrogen-sensitive disease |